A new look at a known drug – telmisartan Review article
Article Sidebar
Published:
Mar 31, 2023
Keywords:
telmisartan, hypertension, angiotensin II AT1 receptor antagonist
Main Article Content
Abstract
The activation of the renin–angiotensin–aldosterone system plays a central role in the pathogenesis of atherosclerosis and cardiovascular disease, therefore RAAS blockade has been suggested to be the most efficient cardioprotective interventions. Telmisartan is favorable for the treatment of patients with hypertension in monotherapy and is also a safe combination with amlodipine or hydrochlorothiazide. Moreover, telmisartan can decrease fasting blood glucose, lower LDL cholesterol, and increase HDL.
Article Details
How to Cite
Kosek-Nikołajczuk, M., & Budnik, M. (2023). A new look at a known drug – telmisartan. Medycyna Faktow (J EBM), 16(1(58), 110-114. https://doi.org/10.24292/01.MF.0123.20
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Akhrass P, McFarlane S. Telmisartan and cardioprotection. Vasc Health Risk Manag. 2011; 7: 677-83.
2. Grupa Robocza Europejskiego Towarzystwa Kardiologicznego (ESC) i Europejskiego Towarzystwa Nadciśnienia Tętniczego (ESH) do spraw postępowania w nadciśnieniu tętniczym. Wytyczne ESC/ESH dotyczące postępowania w nadciśnieniu tętniczym (2018). Kardiol Pol. 2019; 77(2): 71-159.
3. Pinakesty A, Saputra RC, Anggraeni Y et al. The Current Update on the Efficacy of Telmisartan in Patiens with Hypertension: A Systematic Review, ICCvD 2021, AHSR 52, s. 47-61, 2023.
4. Chen R, Suchard MA, Krumholz HM et al. Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers. Hypertension. 2021; 78: 591-603.
5. Zou Z, Xi GL, Yuan HB et al. Telmisartan versus angiotension-converting enzyme inhibitors in the treatment of hypertension: a meta-analysis of randomized controlled trials. J Hum Hypertens. 2009; 23(5): 339-49.
6. Xi GL, Cheng JW, Lu GC. Meta-analysis of randomized controlled trials comparing telmisartan with losartan in the treatment of patients with hypertension. Am J Hypertens. 2008; 21(5): 546-52.
7. Williams B, Lacourciere Y, Schumacher H et al. Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials. J Hum Hypertens. 2009; 23(9): 610-9.
8. Ayza MA, Zewdie KA, Tesfaye BA et al. Anti-Diabetic Effect of Telmisartan Through its Partial PPARɣ-Agonistic Activity. Diabetes Metab Syndr Obes. 2020; 13: 3627-35.
9. Sharma B, Barkate H, Suryawanshi S et al. Retrospective Study to Assess the Effect of Telmisartan on Urine Albumin to Creatinine Ration in Indian Hypertensive Patients. Eur Cardiol. 2021; 16: e63.
10. Barnett AH, Bain SC, Bouter P et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004; 351(19): 1952-61.
11. Makino H, Haneda M, Babazono T et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care. 2007; 30(6): 1577-8.
12. Guo Q, Liu L, Nie P et al. Telmisartan alleviates collagen type III glomerulopathy: A case report with literature review. Exp Ther Med. 2020; 20: 140.
13. Borém LMA, Neto JFR, Brandi IV et al. The role of the angiotensin II type I receptor blocker telmisartan in the treatment of non-alcoholic fatty liver disease: a brief review. Hypertens Res. 2018; 41: 394-405.
14. Liu G, Sung P, Li Y et al. Telmisartan use and risk of dementia in type 2 diabetes patients with hypertension: A population-based cohort study. PLoS Med. 2021; 18(7): e1003707.
2. Grupa Robocza Europejskiego Towarzystwa Kardiologicznego (ESC) i Europejskiego Towarzystwa Nadciśnienia Tętniczego (ESH) do spraw postępowania w nadciśnieniu tętniczym. Wytyczne ESC/ESH dotyczące postępowania w nadciśnieniu tętniczym (2018). Kardiol Pol. 2019; 77(2): 71-159.
3. Pinakesty A, Saputra RC, Anggraeni Y et al. The Current Update on the Efficacy of Telmisartan in Patiens with Hypertension: A Systematic Review, ICCvD 2021, AHSR 52, s. 47-61, 2023.
4. Chen R, Suchard MA, Krumholz HM et al. Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers. Hypertension. 2021; 78: 591-603.
5. Zou Z, Xi GL, Yuan HB et al. Telmisartan versus angiotension-converting enzyme inhibitors in the treatment of hypertension: a meta-analysis of randomized controlled trials. J Hum Hypertens. 2009; 23(5): 339-49.
6. Xi GL, Cheng JW, Lu GC. Meta-analysis of randomized controlled trials comparing telmisartan with losartan in the treatment of patients with hypertension. Am J Hypertens. 2008; 21(5): 546-52.
7. Williams B, Lacourciere Y, Schumacher H et al. Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials. J Hum Hypertens. 2009; 23(9): 610-9.
8. Ayza MA, Zewdie KA, Tesfaye BA et al. Anti-Diabetic Effect of Telmisartan Through its Partial PPARɣ-Agonistic Activity. Diabetes Metab Syndr Obes. 2020; 13: 3627-35.
9. Sharma B, Barkate H, Suryawanshi S et al. Retrospective Study to Assess the Effect of Telmisartan on Urine Albumin to Creatinine Ration in Indian Hypertensive Patients. Eur Cardiol. 2021; 16: e63.
10. Barnett AH, Bain SC, Bouter P et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004; 351(19): 1952-61.
11. Makino H, Haneda M, Babazono T et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care. 2007; 30(6): 1577-8.
12. Guo Q, Liu L, Nie P et al. Telmisartan alleviates collagen type III glomerulopathy: A case report with literature review. Exp Ther Med. 2020; 20: 140.
13. Borém LMA, Neto JFR, Brandi IV et al. The role of the angiotensin II type I receptor blocker telmisartan in the treatment of non-alcoholic fatty liver disease: a brief review. Hypertens Res. 2018; 41: 394-405.
14. Liu G, Sung P, Li Y et al. Telmisartan use and risk of dementia in type 2 diabetes patients with hypertension: A population-based cohort study. PLoS Med. 2021; 18(7): e1003707.